GICS Sector : Healthcare
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally.It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery.
RxSight generated third quarter revenue of $30.3 million, down 14% compared to $35.3 million in the year-ago quarter. The company's Light Adjustable Lens (LAL) revenue was $25.7 million, representing 85% of total revenue. The actual EPS came out at -$0.04, beating estimates of -$0.19. The company's gross margin guidance has been increased, and operating expense guidance remains unchanged. Revenue for the full year 2025 is now expected to be in the range of $125 million to $130 million, narrowed from the prior range of $120 million to $130 million.
Publication Date: Nov -16
The company sold 26,045 LALs during the quarter, with LAL revenue up 6% compared to the third quarter of 2024. RxSight's focus is on strategically expanding its base of LDDs and implanting surgeons. The company's growth model is evolving, with a more diversified approach that includes the strategic addition of new practices and doctors, as well as growing the number of LAL procedures performed by existing accounts. Analysts estimate next year's revenue growth at 4.2%.
RxSight's current valuation metrics include a P/S Ratio of 2.55 and an EV/EBITDA of -10.54. The company's ROE is -11.56%, and ROIC is -14.71%. With a narrowed full-year guidance range, RxSight is poised for sequential growth in 2026, with a focus on LALs and LDDs. As the company continues to expand its global presence, introducing its product beyond Canada, and targeting 20 individual markets where 2/3 of premium procedures are performed, its growth prospects will be closely watched.
The company has made progress in Europe and Asia, with key regulatory infrastructure and commercial initiatives underway. RxSight has launched new practice development and clinical engagement programs, including the MasterClass and Elevate programs, to educate and train doctors. With over 2,000 ophthalmologists having implanted the Light Adjustable Lens, representing roughly 1/5 of the estimated total number of U.S. cataract surgeons, the company is well-positioned for future growth.
RxSight, Inc. to Present at the Piper Sandler Healthcare Conference
Nov -20
RxSight, Inc. (RXST) Q3 2025 Earnings Call Transcript
Nov -06
RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates
Nov -06
RxSight, Inc. Reports Third Quarter 2025 Financial Results
Nov -05
Y Intercept Hong Kong Ltd Invests $1.43 Million in RxSight, Inc. $RXST
Nov -03
RxSight, Inc. to Report Third Quarter 2025 Financial Results on November 5, 2025
Oct -22
RxSight, Inc. to Feature Live Learning Sessions at American Academy of Ophthalmology 2025 Annual Meeting
Oct -16
RXSIGHT ALERT: Bragar Eagel & Squire, P.C. is Investigating RxSight, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Oct -08
RxSight's Light Adjustable Lenses and related capital equipment are driven by increasing demand for cataract surgeries, growing adoption of premium intraocular lenses, and rising awareness of personalized vision correction. Additionally, the company's proprietary technology and expanding sales network contribute to its 10.45% growth.
A type of intraocular lens that can be adjusted after implantation to achieve optimal vision
A data analytics platform that provides insights and visualization tools for ophthalmologists
A suite of surgical planning and guidance tools for ophthalmic surgeons
RxSight, Inc. faces moderate threat from substitutes, as patients may opt for alternative treatments or delay procedures, but the company's innovative technology and strong brand reputation mitigate this risk.
RxSight, Inc. has a diverse customer base, and individual customers do not have significant bargaining power, reducing the risk of price negotiations or demands for customized products.
RxSight, Inc. relies on a few key suppliers for critical components, and while there are alternative suppliers available, the company's dependence on these suppliers gives them some bargaining power.
RxSight, Inc. operates in a highly competitive industry, and new entrants may be attracted to the market, potentially disrupting the company's market share and pricing power.
RxSight, Inc. operates in a highly competitive industry, and intense rivalry among existing players may lead to aggressive pricing, advertising, and innovation, increasing the risk of market share loss.
| Value | |
|---|---|
| Debt Weight | 1.84% |
| Debt Cost | 9.95% |
| Equity Weight | 98.16% |
| Equity Cost | 9.95% |
| WACC | 9.95% |
| Leverage | 1.88% |
Value: 4.5
Growth: 3.9
Quality: 6.1
Yield: 1.0
Momentum: 4.0
Volatility: 8.7
1-Year Total Return ->
Value: 0.2
Growth: 8.0
Quality: 5.9
Yield: 0.0
Momentum: 5.0
Volatility: 6.0
1-Year Total Return ->
Value: 0.0
Growth: 9.8
Quality: 6.9
Yield: 0.0
Momentum: 5.0
Volatility: 2.3
1-Year Total Return ->
Value: 8.2
Growth: 6.6
Quality: 5.3
Yield: 0.0
Momentum: 0.0
Volatility: 1.3
1-Year Total Return ->
Value: 6.4
Growth: 6.2
Quality: 4.2
Yield: 0.0
Momentum: 0.0
Volatility: 3.3
1-Year Total Return ->
Value: 6.4
Growth: 1.8
Quality: 5.3
Yield: 0.0
Momentum: 0.5
Volatility: 4.0
1-Year Total Return ->